上市捷报 | 沙利文助力药明合联生物技术有限公司成功赴港上市(2268.HK)

Wuxing Heliogenics Co., Ltd. (Stock Code:2268.HK) on2023year11month17The company successfully logged into the Hong Kong capital market main board on the same day.ADCand the broader biologics conjugate drug marketCRDMO, and the only company in the world dedicated toADCEquipped with biologics coupling devices and offering comprehensive services from nearby facilitiesCRDMOCurrently, WuXi AppTec's one-stop bioconjugation drug platform provides end-to-endCRDMOServices, including the discovery of bioconjugated drugs, monoclonal antibody intermediates, and bioconjugated drug-related conjugates and payloads, process development, andGood Manufacturing PracticeProduction. Frost & SullivanFrost & Sullivan,Frost & Sullivan, referred to below as 'Frost & Sullivan', provides exclusive industry advisory services for the listing of WuXi AppTec Biologics Co., Ltd. We hereby extend our warmest congratulations on its successful listing.

Wuxing Henglian Biotechnology Co., Ltd. (hereinafter referred to as 'Wuxing Henglian') was established on2023year11month17The company plans to go public on the 1st of July1.78100 million sharesHshare, issue price per share20.60HK$, with the net amount of raised funds being approximately34.83HK$10 billion.

During the process of listing in Hong Kong this time, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support and highlight the issuer's competitive advantages, assisting the issuer, investment banks and other intermediaries in completing the writing of relevant parts of the prospectus (such as overview, competitive advantages and strategy, industry overview, business and other important chapters), helping the issuer complete communication with the Hong Kong Stock Exchange and investors, assisting investors in quickly understanding the market ecosystem and competitive landscape, and assisting the issuer in completing feedback on various industry-related issues from the Hong Kong Stock Exchange, etc.

Investment highlights

The company is a global leader in bioconjugated drugsCRDMO;

The company has the capability to provide interdisciplinary comprehensive services, covering the discovery, research, development, and manufacturing of bioconjugated drugs;

Owns independent R & D technology platform -WuXiDAR4TM;

2022Since [start year] and as of2023year6month30day, there is10China National Pharmaceutical Group Corporation and overseas partners have reached a joint14itemADCTotal amount of externally authorized transactions reached220billions of dollars, this10Among the Chinese companies, eight are clients of ours;

The company has an experienced management team.

According to a report by Frost & Sullivan, by2022Annual Revenue, Company:

Biological conjugated drugCRDMORanked second globally;

Biological conjugated drugCRDMORanked first in China;

It is the only company in the world dedicated toADCEquipped with biologics coupling devices and offering comprehensive services from nearby facilitiesCRDMO;

Expected future8within the yearADCand broader range of bioconjugated drugsCRDMOThe market scale will remain28.4%The speed continues to grow.

globalADCand broader range of bioconjugated drugs

Outsourcing Service Market Overview

ADCThe development of bioconjugated drugs requires a series of interdisciplinary capabilities in biopharmaceuticals and small molecule drugs, which most biopharmaceutical companies do not possess. As a result, the outsourcing rate for bioconjugated drug development has reached about70%, much higher than other biological agents34%Outsourcing rate. With the globalADCRapid growth in pharmaceutical sales, includingADCThe market scale of outsourcing services for other types of conjugated drugs has also grown rapidly.

Source: Frost & Sullivan report

According to a report by Frost & Sullivan,2022GlobalADCAnd the market value of broader bioconjugation drug outsourcing services reaches15billion US dollars2018Year-end2022The compound average annual growth rate for the year is34.5%This growth exceeds the compound annual average growth rate of the overall biologics outsourcing service market for the same period.21.8%are expected2030GlobalADCThe outsourcing service market for broader biologics conjugates will expand significantly, reaching110billion dollars2022Year-end2030The compound average annual growth rate for the year is28.4%.

globalADCand broader range of bioconjugated drugs

Competitive landscape of outsourcing service market

globalADCThe broader outsourcing market for bioconjugated drug development is relatively concentrated, according to a report by Frost & Sullivan, in2022Year, Global Top10bigADCAnd the revenue of broader biologics contract outsourcing service providers accounted for74.3%Among them, the market share of WuXi AppTec Collaborative Innovation Platform is9.8%.

Source: Frost & Sullivan report

In the field of outsourcing services for pharmaceutical R&D and production, Frost & Sullivan has served companies such as Haoyuan Medicine, Dongyao Pharmaceutical, Mabrite, Heyuan Biology, Kanglong Chemical, and Ausbio.

View the full prospectus of WuXi AppTec-Caregen

Frost & Sullivan integrates the globe.62years of consulting experience,25Frost & Sullivan wholeheartedly serves the booming Chinese market, with a global perspective, helping clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The Greater Health Industry is one of the core areas of focus for Frost & Sullivan's research. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listing cases include: Arnao MedicineNASDAQ:ANL), Neusoft Xikang （9686.HK), Youzhiyou2496.HK), Yiming Angke 1541.HK ), Colombo Bay6 990.HK), LaiKai Medicine 2105.HK), Kedex Group2487.HK), Lvz Bio2480.HK), Meis Health 2415.HK), Yaohua MedicinePHECR), Zhongjin Medical （NASDAQ:ZJYL), Yisheng Biology NASDAQ:YS ), Beautiful Countryside 2373.HK), Kangfeng Biology6922.HK), Bona Biotechnology6955.HK), Ideasight1244.HK), Meihao Medical1947.HK), Gaoshi Medical (2407.HK), Lepu Xintai2291.HK), Genstar Biotech9877.HK), HealthyuanJCARE.SW), Leepu MedicalLEPU.SW), DINGDANG HEALTH9886.HK), BAIOSAUTU2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical (1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech Pharmaceuticals2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Scientific & Pharmaceutical2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences（1035.HK) and so on. In terms of the number of submissions, Frost & Sullivan's healthcare team in Hong Kong is involved inIPO listingMaintain an absolute leading position,2018till2022Year after year, it has always ranked first in market share.

since2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: Optoelectronics Technology Group Co., Ltd. 688450.SH ) , Hybrid Integration688249.SH), Wuxi Rilian688531.SH), Maolai Optics688502.SH), Kangwe Century688426.SH), coastal protein688137.SH), Novo Nordisk China (688428.SH), OPPOWAY Biotechnology688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui YAKANG688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the industry. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.